cagrisema vs tirzepatide Novo Nordisk to initiate study assessing CagriSema: Strong Obesity Data, but

Important considerations regarding mood and mental health: Patients with current or previous depression should inform their prescriber before starting Saxenda Any emergence of suicidal thoughts or behaviour requires immediate discontinuation of treatment Other significant mood changes warrant prompt medical review Regular monitoring during the first few months of treatment is advisable for vulnerable individuals Healthcare professionals should adopt a balanced approach, neither dismissing mood concerns nor creating undue alarm

Stephen Appezzato Key Takeaways Federal exclusion of weight-loss drugs forces Medicare GLP-1 utilization into other FDA-approved indications, even as 2024 Part D gross GLP-1 spending reached $27.5 billion across 21.8 million claims

I reached my highest weight ever at 270+ pounds and kept telling myself I was okay with it, but eventually I realized I wanted to make a change

Final Thoughts The field of metabolic peptide research is evolving rapidly, with Europe playing a central role in advancing our understanding of GLP-1 receptor agonists, dual agonists, triple agonists, and other emerging peptide classes